**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | Moffitt Tampa Webcast | **Project Code** | PI4LGR034 |
| **Virtual Project Manager** | Meg Quick | **Clinical Program Manager** | Chelsey Goins |
| **Compliance** | Briana Devaser | **Editor** | Heather Tomlinson |

**Launch Date/Internal Launch Date:**

**Project Type**

Webcast

Downloadable Slides

Podcast

Other:

**Email Blast Included?**

Yes

No

Subject Line:

**Number of E-Blasts**

Only One

Two  
Other Amount:

Dates to Blast or Special Requests:

**Cross Promotion**

Yes

No

If Yes, List Activities:

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By:

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):  
  
Content Available by:

**CME?**

Yes

No

**CME Posttest Link:**

**Webcast/PDS URL:**

www.primeoncology.org/Immuno-oncology\_Tampa\_webcast

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title: Immuno-oncology Mtg 4**

1. **[Meeting-Associated Webcast]---VERIFY with Clinical after the meeting to see what presentation are to be included**

***Immuno-Oncology Comes of Age: Immunotherapy in the Clinic***

**ACTIVITY FEATURES**

[Icon] Interactive Presentation

[Icon] Downloadable Slides

[Icon] CME-Certified

**ACTIVITY OVERVIEW**

This Webcast contains **video and downloadable slides** from the *Immuno-Oncology Comes of Age: Immunotherapy in the Clinic*, a prIME Oncology educational activity that was held on September 12, 2014, in Tampa, Florida.

**FACULTY**

Mario Sznol, MD

Yale Cancer Center

New Haven, Connecticut

**TARGET AUDIENCE**

This educational activity is specifically designed for medical oncologists, nurses, and other healthcare professionals involved in the treatment of patients with cancer in the United States.

**LEARNING OBJECTIVES**

After successful completion of this educational activity, participants should be able to:

* Describe the rationale for incorporating immunotherapy into the treatment plan for patients with melanoma, lung cancer, and renal cell carcinoma
* Outline management plans for the most frequently occurring immune-related adverse events
* Discuss strategies for incorporating immunotherapy into clinical practice, including patient selection and sequencing therapy

**PROVIDER**

This activity is provided by prIME Oncology.

**SUPPORTER**

This educational activity is supported by a grant from Merck & Co., Inc.

**ACTIVITY DATE**

Release Date

November X, 2014

Expiration Date

November X, 2014

**CONTINUING EDUCATION**

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.



prIME Oncology designates this enduring activity for a maximum of *1.0* *AMA PRA Category 1 Credits™.*Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Method of Participation**  
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you.

Technical requirements may be found under the [Terms of Use](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx).

Links to the posttest are available on the video player pages.

In order to claim credit for this activity, a score of 80% or higher is required.

**Disclosure of Relevant Financial Relationships**  
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

**Faculty Disclosures**The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Sznol has disclosed that he has received consulting fees from Amgen, Amphivena, Anaeropharma, BeiGene, Bristol-Myers Squibb, Genentech/Roche, Immune Design, Kyowa-Kirin, Lion Biotechnologies, MedImmune, Merus, Nektar, NeoStem, Seattle Genetics, and Symphogen. He also owns interest in Amphivena. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

Chelsey Goins, PhD (clinical content reviewer/planner) – no relevant financial relationships  
Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

**Disclosure Regarding Unlabeled Use**

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

**Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

**MOBILE APP VIEW ACTIVITY TEXT PER VIDEO**Insert presentation-specific text for the “View Activity” action item on the mobile app.